Follow us on LinkedIn - https://www.linkedin.com/company/fatty-liver-alliance/
Advocacy and Educational Collaborations
EASL European Association for the Study of the Liver
EASL is Building New Synergies
Our strategic directions
SCIENCE
To be a key facilitator of excellence in liver research and liver-related innovation.
EDUCATION
To be the prime resource for liver-related education and professional development of Health Care Professionals at all layers in the health care system as well as patients.
ADVOCACY
We aim to advocate for the highest standards of care for patients with liver conditions.
Global NASH Council
EASL is Building New Synergies
Non-alcoholic steatohepatitis (NASH) or metabolic dysfunction associated steatohepatitis (MASH) is increasingly recognized as one of the most common causes of liver disease worldwide. In order to understand the global impact of this disease, The Global NASH Council was created to include renowned experts from different regions of the world with interest in NASH/MASH to collaborate and exchange their views about NASH. The Global NASH Council includes 50 countries from all the continents across the globe with 170 members. Members of the Council carry out collaborative projects to better understand the burden of NASH across the world. For more details, please see our Mission, Vision and Values. As of January 2024, the Global NASH Council has been endorsed by a number of organizations.
Inventiva
We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.
Aegle Medical Solutions
Who We Are
Our company represents world-class equipment manufacturers and innovative technology providers who specialize in advanced medical imaging, medical equipment, SaaS, and more services.
Surfing the NASH Tsunami
NASH Tsunami is a weekly podcast in which a panel of experts discusses commercial developments of NASH.
Every week, a global community of Fatty Liver Disease stakeholders comes together to explore the most important challenges in diagnosing, treating, and developing medications for patients with Fatty Liver Diseases.
Liver Patients International
Our Vision
Liver Patients International (LPI) has a vision where all patients affected by liver disease, wherever they live in the world, have access to timely diagnosis, appropriate healthcare, the best possible quality of life, and that their voice is part of the decision-making process.
Our Mission
LPI will keep patients at the center of all that it does. We work in a progressive and collaborative way, ensuring meaningful engagement and partnerships with other stakeholders. We represent and advocate for all patients affected by liver disease in both policy and operational contexts and promote equal access to effective areas of liver healthcare.
PPD
We thank PPD for inviting us to be part of their Patient Journey work, and to participate in an online live webinar about the Patient Voice in clinical studies.
PPD is a Leading Global Contract Research Organization Focused on Delivering Life-changing Therapies.
Arizona Liver Health
Our mission is to provide state-of-the-art, innovative, and compassionate care to patients affected by liver diseases.
Our facility was designed to accommodate our cutting edge diagnostic tools, chronic disease care and clinical trails of novel therapeutics for patients with various liver diseases.
Evido Health
Evido Health is a data-driven health tech company that specializes in ensuring the timely detection of individuals with steatotic liver disease (SLD). They are introducing a new diagnostic platform that leverages existing healthcare data to provide accurate assessments and segmentation of liver fibrosis. Evido Health is based in Denmark and has its origins in over a decade of clinical research.
Siemens Healthineers
Our purpose
When our health is at risk, we rely on physicians to make the best possible decisions – from quick, early diagnoses to the most effective treatments and follow-ups. By constantly bringing breakthrough innovations to market, we help healthcare professionals to deliver high-quality care, leading to the best possible outcome for patients.
Our portfolio of products, services, and solutions is at the center of clinical decision-making and treatment pathways. Patient-centered innovation has been and always will be at the core of our company. We aspire to create better outcomes and experiences for patients no matter where they live or what they are facing.
We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably.
This is why we give our best every day, to improve the lives of patients and their families.
Volunteer Opportunities
Volunteers are the backbone of our organization. We offer a variety of opportunities for individuals and groups to get involved and make a difference in the lives of those we serve.
Advocacy and Educational Collaborations
Global Liver Alliance - Liver Action Network
This initiative connects liver patients, caregivers, and providers with policymakers on urgent policy changes to improve the liver patient experience.
Canadian MASLD Network (CanMASLD)
We thank CanMASLD for the collaboration on the annual MASLD and MASH Primary Care Summit and the ongoing work we do together for Canadian Research and Patient Education.
CanMASLD: The Canadian MASLD Network is a collaborative organization of health care professionals from across Canada with a primary interest in enhancing understanding, care of, education and research in persons with MASLD with a vision of best practices for this disease state.
Novo Nordisk
We thank Novo Nordisk for their support for our Annual NAFLD and NASH Primary Care Summit and for our Westmount Patient Education, Cafe Scientifique.
Novo Nordisk: "We are acting on our purpose to defeat serious chronic diseases by expanding our commitment in areas of high unmet need, including metabolic dysfunction-associated steatohepatitis (MASH).
MASH is also known as nonalcoholic steatohepatitis (NASH).
This is a disease that impacts a growing number of people worldwide, and we welcome you to learn more about its causes, symptoms, and how to improve liver health, while also discovering our research and development efforts to help address the unmet medical need in this disease area."
Canadian Institutes of Health Research (CIHR)
The Canadian Institutes of Health Research (CIHR) is Canada's federal funding agency for health research. Composed of 13 Institutes, we collaborate with partners and researchers to support the discoveries and innovations that improve our health and strengthen our health care system.
ELPA
ELPA’s aim is to promote the interests of people with liver disease and in particular: to highlight the size of the problem; to promote awareness and prevention; to address the low profile of liver disease as compared to other areas of medicine such as heart disease; to share experience of successful initiatives; to work with professional bodies such as EASL and with the EU to ensure that treatment and care are harmonised across Europe to the highest standards.
Canadian Obesity Advocacy Network (COAN)
The Canadian Obesity Advocacy Network (COAN) is a diverse network of forward-thinking NGOs, companies, foundations, agencies, academics, clinicians and groups of people living with obesity that have come together with the purpose of changing the narrative of obesity in Canada. The COAN sits under the umbrella of Obesity Canada and is committed to collectively addressing bias and stigma, education, access to care and advocacy in Canada.
Regeneron
We thank Regeneron for their grant support in 2023.
Regeneron: "PUSH THE BOUNDS OF SCIENCE
MAKE LIFE-CHANGING MEDICINES"
awareNASH
AwareNASH is a research project with the objective to educate clinicians managing patients with NAFLD and NASH on the importance of prompt diagnosis (especially in the case of NASH), along with the relationship of NAFLD/NASH to metabolic disease and CVD. It is funded by an independent educational grant provided by Pfizer.
Annual NASH Summit
The Annual NASH Summit is your best opportunity to unite with fellow NASH drug developers to gain critical updates on the trailblazing research you need to meaningfully reassess your therapeutic approach and optimize your pipeline strategy for the future.
Metabolism and Target Organ Damage
Metabolism and Target Organ Damage (M&TOD, https://mtodjournal.net ) is an international, peer-reviewed, open-access interdisciplinary journal that provides an online platform for the publication of clinical, basic, and translational studies. It covers (cardio)-metabolic disorders per se, such as obesity, diabetes, dyslipidemias, arterial hypertension, and hyperuricemia in all age groups. Of note, this journal will emphasize the role of these metabolic disorders as either effectors/amplifiers or consequences of the development and progression of injuries to target organs including but not limited to the cardiovascular system, the liver, kidneys, and the pancreas. Specific applications in metabolic disorders are as follows: history of the disease, epidemiology, prevention, natural history, genetics, cell, and molecular biology, pathobiochemistry, physiopathology, anatomic pathology, clinical chemistry, pharmaceutical chemistry, pharmacology, psychology, psychiatry, statistics, and immunology.
Our NAFLD Studies: https://mtodjournal.net/search/search?clearPageContext=1&searchJournal=26&searchVal=fatty+liver
badgut.org
We’re committed to improving the lives of people with gastrointestinal and liver conditions, supporting research, advocating for appropriate patient access to healthcare, and promoting gastrointestinal and liver health.